4//SEC Filing
Protea Biosciences Group, Inc. 4
Accession 0001144204-15-018866
CIK 0001335103operating
Filed
Mar 26, 8:00 PM ET
Accepted
Mar 27, 1:21 PM ET
Size
8.1 KB
Accession
0001144204-15-018866
Insider Transaction Report
Form 4
ANTOLINE STEVE
Director10% Owner
Transactions
- Other
Warrant (right to buy)
2015-03-20+1,100,523→ 1,100,523 total(indirect: See Footnote)Exercise: $0.50From: 2015-03-20Exp: 2020-03-20→ Common Stock (1,100,523 underlying) - Other
Common Stock
2015-03-20+2,201,046→ 14,885,481 total(indirect: See Footnote)
Footnotes (2)
- [F1]On March 20, 2015, the Issuer's Board of Directors authorized the conversion of an aggregate of $$341,084.81 principal amount of, and $192,784.63 of accrued interest on promissory notes issued by the Issuer to Summit Resources, Inc. ("Summit"), and $16,392.14 of accounts payable by the Issuer to Summit, into 2,201,046 units of securities, each unit consisting of one share of the Issuer's common stock and a five-year warrant to purchase one-half share of Common Stock, at an exercise price of $0.50 per whole share, at a conversion price of $0.25 per unit. None of these obligations was convertible by its terms.
- [F2]Represents the shares of Common Stock owned of record by Summit. Steve Antoline has voting and dispositive control over any securities owned of record by Summit and may be deemed to beneficially own the shares of common stock held of record by Summit.
Documents
Issuer
Protea Biosciences Group, Inc.
CIK 0001335103
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001335103
Filing Metadata
- Form type
- 4
- Filed
- Mar 26, 8:00 PM ET
- Accepted
- Mar 27, 1:21 PM ET
- Size
- 8.1 KB